Alpine Immune Sciences Inc (ALPN)
Market Closed
17 May, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary 
SIX $
64. 97
+0.01
+0.0154%
$
4.46B Market Cap
- P/E Ratio
- Div Yield
4.29M Volume
-1.08 Eps
$ 64.96
Previous Close Want to track ALPN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ALPN closed Friday higher at $64.97, an increase of 0.0154% from Thursday's close, completing a monthly increase of 0% or $64.97. Over the past 12 months, ALPN stock gained 0%.
ALPN is not paying dividends to its shareholders.
The last earnings report, released on Mar 17, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.14%, based on the last three reports.
Alpine Immune Sciences Inc has completed 1 stock splits, with the recent split occurring on Jul 25, 2017.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).
Alpine Immune Sciences Inc (ALPN) FAQ
What is the stock price today?
The current price is $64.97.
On which exchange is it traded?
Alpine Immune Sciences Inc is listed on NASDAQ (NMS).
What is its stock symbol?
The ticker symbol is ALPN.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 4.46B.
Has Alpine Immune Sciences Inc ever had a stock split?
Alpine Immune Sciences Inc had 1 splits and the recent split was on Jul 25, 2017.
Alpine Immune Sciences Inc Profile
| Biotechnology Industry | Healthcare Sector | Mitchell H. Gold CEO | NASDAQ (NMS) Exchange | 02083G100 CUSIP |
| US Country | 142 Employees | - Last Dividend | 25 Jul 2017 Last Split | 17 Jun 2015 IPO Date |
Overview
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, established in 2007. The company specializes in the field of immunotherapy, focusing on the development of innovative treatments for autoimmune and inflammatory diseases through advanced protein engineering technologies. Alpine Immune Sciences is dedicated to addressing unmet medical needs by pioneering novel therapeutics designed to modulate the immune system.
Products and Services
The company's development pipeline showcases a range of immunotherapy candidates aimed at treating various autoimmune and inflammatory conditions, each leveraging unique mechanisms of action:
- Povetacicept: Currently in Phase 2 clinical trials, Povetacicept is a pioneering dual B cell cytokine antagonist. This candidate seeks to offer a new approach for treating a spectrum of autoimmune and inflammatory diseases by targeting key pathways involved in the immune response.
- Acazicolcept: Acazicolcept is in the preclinical trial phase and functions as a dual inhibitor targeting the CD28 and ICOS T cell costimulatory pathways. This mechanism is particularly focused on the treatment of systemic lupus erythematosus, aiming to provide a novel therapeutic option for patients suffering from this challenging condition.
- RUBY-3: RUBY-3 has successfully completed Phase 1 clinical trials and is designed for the treatment of glomerulonephritis. This therapeutic candidate represents Alpine Immune Sciences' commitment to developing innovative solutions for kidney-related inflammatory diseases.
- RUBY-4: Having completed Phase 1 clinical trials, RUBY-4 is aimed at addressing cytopenias. This program highlights the company's efforts to expand its pipeline into therapies that could potentially treat a range of hematological disorders.
Contact Information
Address: 188 East Blaine Street
Phone: 206 788 4545
Website: https://www.alpineimmunesciences.com
